Evidence map›Paper›PMID 26205255›Full record

ArticleActa neuropathologica communications2015

Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.

Mathieu Bourdenx, Sandra Dovero, Michel Engeln, Simone Bido, Matthieu F Bastide, Nathalie Dutheil, Isabel Vollenweider, Laetitia Baud, Camille Piron, Virginie Grouthier and 11 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.

  1. Impact of aging on animal models of Parkinson's disease.Frontiers in aging neuroscience · 2022
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 5 countries.

Mathieu BourdenxUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Sandra DoveroUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Michel EngelnUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Simone BidoUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Matthieu F BastideUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Nathalie DutheilUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Isabel VollenweiderInternational Paraplegic Foundation chair in spinal cord Repair, Center for Neuroprosthetics and Brain Mind Institute, School of Life Sciences, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Laetitia BaudInternational Paraplegic Foundation chair in spinal cord Repair, Center for Neuroprosthetics and Brain Mind Institute, School of Life Sciences, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Camille PironUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Virginie GrouthierUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Thomas BoraudUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
Grégory PorrasMotac Neuroscience, Manchester, UK.
Qin LiMotac Neuroscience, Manchester, UK.
Veerle BaekelandtDepartment of Neurosciences and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, Laboratory for Neurobiology and Gene Therapy, Kapucijnenvoer 33, box 7001, 3000, Leuven, Belgium.
Dieter SchellerParkinson's Disease Pharmacology, UCB Pharma S.A., Braine L'Alleud, B-1420, Belgium.
Anne MichelParkinson's Disease Pharmacology, UCB Pharma S.A., Braine L'Alleud, B-1420, Belgium.
Pierre-Olivier FernagutUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France.
François GeorgesUniversity de Bordeaux, Interdisciplinary Institute for Neuroscience, UMR5297, Bordeaux, France.
Grégoire CourtineInternational Paraplegic Foundation chair in spinal cord Repair, Center for Neuroprosthetics and Brain Mind Institute, School of Life Sciences, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Erwan BezardUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France. erwan.bezard@u-bordeaux.fr.
Benjamin DehayUniversity de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France. benjamin.dehay@u-bordeaux.fr.
Institut des Maladies Neurodégénératives · FRCentre National de la Recherche Scientifique · FRÉcole Polytechnique Fédérale de Lausanne · CHUCB Pharma (Belgium) · BEChinese Academy of Medical Sciences & Peking Union Medical College · CNMotac Neuroscience (United Kingdom) · GBVIB-KU Leuven Center for Brain & Disease Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons as well as the presence of proteinaceous inclusions named Lewy bodies. α-synuclein (α-syn) is a major constituent of Lewy bodies, and the first disease-causing protein characterized in PD. Several α-syn-based animal models of PD have been developed to investigate the pathophysiology of PD, but none of them recapitulate the full picture of the disease. Ageing is the most compelling and major risk factor for developing PD but its impact on α-syn toxicity remains however unexplored. In this study, we developed and exploited a recombinant adeno-associated viral (AAV) vector of serotype 9 overexpressing mutated α-syn to elucidate the influence of ageing on the dynamics of PD-related neurodegeneration associated with α-syn pathology in different mammalian species.

resultsIdentical AAV pseudotype 2/9 vectors carrying the DNA for human mutant p.A53T α-syn were injected into the substantia nigra to induce neurodegeneration and synucleinopathy in mice, rats and monkeys. Rats were used first to validate the ability of this serotype to replicate α-syn pathology and second to investigate the relationship between the kinetics of α-syn-induced nigrostriatal degeneration and the progressive onset of motor dysfunctions, strikingly reminiscent of the impairments observed in PD patients. In mice, AAV2/9-hα-syn injection into the substantia nigra was associated with accumulation of α-syn and phosphorylated hα-syn, regardless of mouse strain. However, phenotypic mutants with either accelerated senescence or resistance to senescence did not display differential susceptibility to hα-syn overexpression. Of note, p-α-syn levels correlated with nigrostriatal degeneration in mice. In monkeys, hα-syn-induced degeneration of the nigrostriatal pathway was not affected by the age of the animals. Unlike mice, monkeys did not exhibit correlations between levels of phosphorylated α-syn and neurodegeneration.

conclusionsIn conclusion, AAV2/9-mediated hα-syn induces robust nigrostriatal neurodegeneration in mice, rats and monkeys, allowing translational comparisons among species. Ageing, however, neither exacerbated nigrostriatal neurodegeneration nor α-syn pathology per se. Our unprecedented multi-species investigation thus favours the multiple-hit hypothesis for PD wherein ageing would merely be an aggravating, additive, factor superimposed upon an independent disease process.

Indexed as

Agingalpha-SynucleinAnimalsBiomechanical PhenomenaCallithrixDisease Models, AnimalDopamine Plasma Membrane Transport ProteinsGreen Fluorescent ProteinsHumansMiceMotor ActivityMPTP PoisoningPrincipal Component AnalysisPsychomotor PerformanceRatsStriatonigral Degenerationalpha-SynucleinDopamine Plasma Membrane Transport ProteinsGreen Fluorescent ProteinsTyrosine 3-Monooxygenase

Identifiers

PMID26205255
PMCPMC4513748
OpenAlexW1957569525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.